Can multi- DARPins overcome the limitations of traditional cancer therapies?




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Can multi- DARPins overcome the limitations of traditional cancer therapies?
Released on: May 16, 2016. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    DARPins are a new class of small protein therapies derived from natural Ankyrin Repeat Proteins.
  • Summary
  • Transcript
  • Participants
  • Company
DARPins are a new class of small protein therapies derived from natural Ankyrin Repeat Proteins. Christian Zahnd, CEO of Molecular Partners, talks about the key successes and future applications of multi-DARPin technology.
DARPins are a new class of small protein therapies derived from natural Ankyrin Repeat Proteins. Christian Zahnd, CEO of Molecular Partners, talks about the key successes and future applications of multi-DARPin technology.
Dr. Christian Zahnd is Chief Executive Officer of Molecular Partners and a member of the Company’s Board of Directors. Christian co-founded Molecular Partners and has been a member of the Company’s management team since its inception in 2004. He graduated with a Master of Science degree from the ETH Zurich and earned his PhD in Molecular Biology from the University of Zurich. His research focused on antibodies and antibody fragments, which he studied independently and through academic and industry collaborations.
Molecular Partners
Molecular Partners is a privately owned biopharmaceutical company, located in Zurich, Switzerland, that is pioneering the development of a novel class of targeted protein therapeutics termed DARPins. DARPins are as target specific and potent as monoclonal antibodies. Yet, being small proteins, they overcome the known limitations of conventional protein-based therapeutic approaches. We address real medical needs and develop cutting-edge medicine based on innovative DARPin products. The DARPin platform has rapidly generated a differentiated pipeline of drug candidates. The most advanced DARPin is MP0112, an inhibitor of VEGF, which is in Phase I/IIa development. Further products are in research and preclinical development. We balance our internal drug development efforts with strategic alliances with renowned pharmaceutical companies. Molecular Partners is backed by a very strong international syndicate of institutional and corporate investors.